Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study by Liu, Joyce F, Dr, Barry, William T, PhD, Birrer, Michael, MD, Lee, Jung-Min, MD, Buckanovich, Ronald J, MD, Fleming, Gini F, Prof, Rimel, BJ, MD, Buss, Mary K, MD, Nattam, Sreenivasa, MD, Hurteau, Jean, MD, Luo, Weixiu, MS, Quy, Philippa, MA, Whalen, Christin, BSN, Obermayer, Lisa, BA, Lee, Hang, PhD, Winer, Eric P, Prof, Kohn, Elise C, MD, Ivy, S Percy, MD, Matulonis, Ursula A, MD

Get full text

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study by Cohen, Ezra EW, Dr, Davis, Darren W, PhD, Karrison, Theodore G, PhD, Seiwert, Tanguy Y, MD, Wong, Stuart J, MD, Nattam, Sreenivasa, MD, Kozloff, Mark F, MD, Clark, Joseph I, MD, Yan, Duen-Hwa, PhD, Liu, Wen, MD, Pierce, Carolyn, BA, Dancey, Janet E, MD, Stenson, Kerstin, MD, Blair, Elizabeth, MD, Dekker, Allison, BSN, Vokes, Everett E, Prof

Get full text